BRPI1011103B8 - composição para tratar infertilidade masculina e usos de ácido d-aspártico e de ácido l-aspártico - Google Patents

composição para tratar infertilidade masculina e usos de ácido d-aspártico e de ácido l-aspártico

Info

Publication number
BRPI1011103B8
BRPI1011103B8 BRPI1011103A BRPI1011103A BRPI1011103B8 BR PI1011103 B8 BRPI1011103 B8 BR PI1011103B8 BR PI1011103 A BRPI1011103 A BR PI1011103A BR PI1011103 A BRPI1011103 A BR PI1011103A BR PI1011103 B8 BRPI1011103 B8 BR PI1011103B8
Authority
BR
Brazil
Prior art keywords
aspartic acid
composition
male infertility
treat male
aspartic
Prior art date
Application number
BRPI1011103A
Other languages
English (en)
Inventor
D'aniello Enrico
D'aniello Salvatore
Original Assignee
Merck Serono S P A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Serono S P A filed Critical Merck Serono S P A
Publication of BRPI1011103A2 publication Critical patent/BRPI1011103A2/pt
Publication of BRPI1011103B1 publication Critical patent/BRPI1011103B1/pt
Publication of BRPI1011103B8 publication Critical patent/BRPI1011103B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fodder In General (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

composição para tratar infertilidade masculina e uso. a presente invenção refere-se ao uso de uma combinação que consiste nos ácidos d-aspártico e l-aspático ou l-aspático isolado para estimular a atividade procriativa no homem aumentando o número e a motilidade dos espermatozoides.
BRPI1011103A 2009-05-19 2010-05-19 composição para tratar infertilidade masculina e usos de ácido d-aspártico e de ácido l-aspártico BRPI1011103B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2009A000253 2009-05-19
ITRM2009A000253A IT1395957B1 (it) 2009-05-19 2009-05-19 Uso di una combinazione di d-aspartato e l-aspartato per il trattamento della infertilita' maschile.
PCT/IT2010/000222 WO2010134117A1 (en) 2009-05-19 2010-05-19 Use of a combination of d-aspartic and l-aspartic acids or salts thereof for the treatment of male infertility

Publications (3)

Publication Number Publication Date
BRPI1011103A2 BRPI1011103A2 (pt) 2017-05-09
BRPI1011103B1 BRPI1011103B1 (pt) 2021-04-13
BRPI1011103B8 true BRPI1011103B8 (pt) 2021-05-25

Family

ID=41262507

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1011103A BRPI1011103B8 (pt) 2009-05-19 2010-05-19 composição para tratar infertilidade masculina e usos de ácido d-aspártico e de ácido l-aspártico

Country Status (16)

Country Link
US (3) US20120095100A1 (pt)
EP (1) EP2432463B1 (pt)
JP (1) JP5833545B2 (pt)
KR (3) KR20160132500A (pt)
CN (1) CN102438611A (pt)
AU (1) AU2010250747B2 (pt)
BR (1) BRPI1011103B8 (pt)
CA (1) CA2759674C (pt)
EA (1) EA021832B1 (pt)
ES (1) ES2555387T3 (pt)
IL (1) IL216112A (pt)
IT (2) IT1395957B1 (pt)
MX (1) MX2011012323A (pt)
SG (1) SG175304A1 (pt)
WO (1) WO2010134117A1 (pt)
ZA (1) ZA201107764B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1395957B1 (it) 2009-05-19 2012-11-02 Pharmaguida S R L Uso di una combinazione di d-aspartato e l-aspartato per il trattamento della infertilita' maschile.
CN102603551A (zh) * 2011-12-20 2012-07-25 安徽华恒生物工程有限公司 一种d-天冬氨酸二价盐及其制备方法
CN102631663B (zh) * 2012-05-02 2014-08-20 张风帆 一种治疗男性不育、阳痿早泄的制剂及其应用
AP2016009159A0 (en) * 2013-11-12 2016-04-30 Cadila Healthcare Ltd Formulation for gonadotropins
CN106563124A (zh) * 2016-10-19 2017-04-19 广西大学 硫辛酸作为疫苗佐剂的应用
FR3070263B1 (fr) * 2017-08-28 2020-07-24 Serelys Pharma S A M Composition pour son utilisation dans le traitement et/ou la prevention de l’infertilite

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607570D0 (en) * 1986-03-26 1986-04-30 Euro Celtique Sa Vaginal pharmaceutical preparation
US5397786A (en) * 1993-01-08 1995-03-14 Simone; Charles B. Rehydration drink
KR970008105B1 (ko) * 1993-06-28 1997-05-21 주식회사 미원 L-아스파테이트 또는 아스파라긴을 유효성분으로 함유하는 알콜성 장해 보호제 및 그의 제조방법
US5863940A (en) * 1997-12-01 1999-01-26 Sigma-Tau Healthscience S.P.A. Medicament and therapeutical method for treating idiopathic asthenozoospermia
US6632449B2 (en) * 2001-11-20 2003-10-14 The Procter & Gamble Co. Compositions and kits comprising a defined boron compound and methods of their preparation
WO2005120488A1 (en) * 2004-06-10 2005-12-22 Sara Sarig Aspartic acid for the regeneration of bone matter
NZ556499A (en) * 2005-02-04 2011-02-25 Repros Therapeutics Inc Methods and materials with trans-clomiphene for the treatment of male infertility
US20060210692A1 (en) * 2005-03-18 2006-09-21 Mower Thomas E Baby food composition
ITRM20050468A1 (it) * 2005-09-14 2007-03-15 Marzocchella Teresa Uso dell'acido d-aspartico o dei suoi sali per il trattamento della infertilita' maschile.
US8202908B1 (en) * 2008-03-28 2012-06-19 Thermolife International, Llc D-aspartic acid supplement
IT1395957B1 (it) 2009-05-19 2012-11-02 Pharmaguida S R L Uso di una combinazione di d-aspartato e l-aspartato per il trattamento della infertilita' maschile.

Also Published As

Publication number Publication date
CN102438611A (zh) 2012-05-02
ITRM20100255A1 (it) 2010-11-20
EA201171431A1 (ru) 2012-05-30
IL216112A0 (en) 2012-01-31
ITRM20090253A1 (it) 2010-11-20
AU2010250747A2 (en) 2012-01-12
ES2555387T3 (es) 2015-12-30
BRPI1011103B1 (pt) 2021-04-13
MX2011012323A (es) 2012-03-07
KR20120038408A (ko) 2012-04-23
US20120095100A1 (en) 2012-04-19
CA2759674A1 (en) 2010-11-25
US10342826B2 (en) 2019-07-09
KR20180137605A (ko) 2018-12-27
JP2012527448A (ja) 2012-11-08
SG175304A1 (en) 2011-12-29
US20140271595A1 (en) 2014-09-18
EP2432463A1 (en) 2012-03-28
BRPI1011103A2 (pt) 2017-05-09
AU2010250747B2 (en) 2014-10-23
IT1395957B1 (it) 2012-11-02
US20190328778A1 (en) 2019-10-31
IL216112A (en) 2016-02-29
EP2432463B1 (en) 2015-09-30
WO2010134117A1 (en) 2010-11-25
KR102054942B1 (ko) 2019-12-11
ZA201107764B (en) 2012-12-27
IT1400312B1 (it) 2013-05-24
CA2759674C (en) 2017-02-14
JP5833545B2 (ja) 2015-12-16
EA021832B1 (ru) 2015-09-30
KR20160132500A (ko) 2016-11-18
US11524031B2 (en) 2022-12-13
AU2010250747A1 (en) 2011-11-10

Similar Documents

Publication Publication Date Title
GT201200056A (es) Conjugados de niacina y ácidos grasos y sus usos
BRPI1011103B8 (pt) composição para tratar infertilidade masculina e usos de ácido d-aspártico e de ácido l-aspártico
BR112016006926A2 (pt) composições compreendendo um conjugado de ácido quínico com ácido cafeico, usos terapêuticos e cosméticos
ECSP11011044A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
ECSP10010697A (es) Inhibidores de dpp-iv para uso en el tratamiento de nafld
HN2011002406A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
BR112012007234A2 (pt) combinação farmacêutica compreendendo inibidor de dpp-4 e metformina, bem como seu uso e seu processo de preparação
BRPI1000320B8 (pt) Composições e métodos para tratar sinais de envelhecimento da pele
BRPI0802241A2 (pt) células-tronco mesenquimais e seus usos
BR112013000776A2 (pt) método e formulação para tratamento de deficiência de ácido siálico
BRPI0712816B8 (pt) compostos de pirrolpirimidina e seus usos
UA111464C2 (uk) Композиція, що містить моногліцериди органічних кислот c1-c7 та гліцерин, та її застосування як протибактеріального та протипліснявого засобу
WO2011009759A3 (de) Verwendung von dihydroquercetin und mindestens einer aminosäure zur positiven beeinflussung des natürlichen pigmentierungsprozesses
CR10343A (es) Aminotetrahidropiranos como inihibidores de dipeptidil peptidasa-iv para el tratamiento o prevencion de diabetes
MX338712B (es) Composicion farmaceutica que comprende linagliptina y opcionalmente un inhibidor de sglt2, y usos de la misma.
GT201100205A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
EP2418945A4 (en) Mineral salt-sulfuric acid compositions and methods for their use
BRPI0913574A2 (pt) composição de tratamento de acne compreendendo nanoprata e usos
BR112014015940A2 (pt) composição de novo fármaco de carboidrato para tratamento de doenças humanas
CL2009001484A1 (es) Sal glicinato de metformina; composición farmacéutica que comprende la sal; y su uso para tratar la hiperglicemia.
TN2011000482A1 (en) Organic compounds and their uses
ECSP10010494A (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
BR112012005044A2 (pt) composições que compreendem tramadol e celecoxib no tratamento de dor.
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
BR112013021889A2 (pt) método para a indução de resistência a doenças em plantas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME MEDIDA CAUTELAR DE 07/04/2021 - ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/05/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF